Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort.


Journal

Journal of neurology, neurosurgery, and psychiatry
ISSN: 1468-330X
Titre abrégé: J Neurol Neurosurg Psychiatry
Pays: England
ID NLM: 2985191R

Informations de publication

Date de publication:
06 2019
Historique:
received: 15 09 2018
revised: 09 12 2018
accepted: 19 12 2018
pubmed: 12 1 2019
medline: 14 3 2020
entrez: 12 1 2019
Statut: ppublish

Résumé

To assess the role of body mass index (BMI) and of the rate of weight loss as prognostic factors in amyotrophic lateral sclerosis (ALS) and to explore the clinical correlates of weight loss in the early phases of the disease. The study cohort included all ALS patients in Piemonte/Valle d'Aosta in the 2007-2011 period. Overall survival and the probability of death/tracheostomy at 18 months (logistic regression model) were calculated. Of the 712 patients, 620 (87.1%) were included in the study. Patients ' survival was related to the mean monthly percentage of weight loss at diagnosis (p<0.0001), but not to pre-morbid BMI or BMI at diagnosis. Spinal onset patients with dysphagia at diagnosis had a median survival similar to bulbar onset patients. About 20% of spinal onset patients without dysphagia at diagnosis had severe weight loss and initial respiratory impairment, and had a median survival time similar to bulbar onset patients. The rate of weight loss from onset to diagnosis was found to be a strong and independent prognostic factor in ALS. Weight loss was mainly due to the reduction of nutritional intake related to dysphagia, but a subgroup of spinal onset patients without dysphagia at diagnosis had a severe weight loss and an outcome similar to bulbar patients. According to our findings, we recommend that in clinical trials patients should be stratified according to the presence of dysphagia at the time of enrolment and not by site of onset of symptoms.

Identifiants

pubmed: 30630957
pii: jnnp-2018-319611
doi: 10.1136/jnnp-2018-319611
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

666-673

Investigateurs

Stefania Cammarosano (S)
Rosario Vasta (R)
Maria Claudia Torrieri (M)
Luca Solero (L)
Marinella Clerico (M)
Stefania De Mercanti (S)
Alessandro Mauro (A)
Luca Pradotto (L)
Fabiola De Marchi (F)
Luisa Sosso (L)
Daniela Leotta (D)
Lucia Appendino (L)
Daniele Imperiale (D)
Roberto Cavallo (R)
Claudio Geda (C)
Fabio Poglio (F)
Paola Santimaria (P)
Umberto Massazza (U)
Antonio Villani (A)
Roberto Conti (R)
Luigi C Ruiz (LC)
Mario Palermo (M)
Franco Vergnano (F)
Eugenia Rota (E)
Maria Teresa Penza (M)
Marco Aguggia (M)
Piero Meineri (P)
Paolo Ghiglione (P)
Nicola Launaro (N)
Giuseppe Astegiano (G)
Giovanni Corso (G)

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: AC serves on a scientific advisory board for Mitsubishi Tanabe, Roche, and Cytokinetics.

Auteurs

Cristina Moglia (C)

ALS Center, 'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Turin, Italy.
Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Torino, Italy.

Andrea Calvo (A)

ALS Center, 'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Turin, Italy.
Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Torino, Italy.

Maurizio Grassano (M)

ALS Center, 'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Turin, Italy.

Antonio Canosa (A)

ALS Center, 'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Turin, Italy.

Umberto Manera (U)

ALS Center, 'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Turin, Italy.

Fabrizio D'Ovidio (F)

ALS Center, 'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Turin, Italy.

Alessandro Bombaci (A)

ALS Center, 'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Turin, Italy.

Enrica Bersano (E)

ALS Center, Department of Neurology, Azienda Ospedaliera Universitaria Maggiore della Carità, Novara, Italy.

Letizia Mazzini (L)

ALS Center, Department of Neurology, Azienda Ospedaliera Universitaria Maggiore della Carità, Novara, Italy.

Gabriele Mora (G)

ALS Center, Istituti Clinici Scientifici Maugeri IRCCS, Milan, Italy.

Adriano Chiò (A)

ALS Center, 'Rita Levi Montalcini' Department of Neuroscience, University of Torino, Turin, Italy achio@usa.net.
Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Torino, Italy.
National Research Council (CNR), Institute of Cognitive Sciences and Technologies, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH